# Convergen Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/convergen-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.convergenbio.com
- Total disclosed funding: $10M
- Latest round: Seed (Dec 8, 2025)
- Investors on record: 4

## About

Based in Suzhou, China and founded in 2020, Suzhou Convergen Biopharmaceuticals Co., Ltd., trading under the name Convergen, provides targeted protein degradation therapies for the healthcare industry. The firm was established to address unmet medical needs in the field of neurodegenerative diseases. In December 2025, it closed a seed funding from Qiming Venture Partners.

The company works with large pharmaceutical companies and medical research institutions to provide innovative protein degradation technologies and drug pipelines. Product offerings include the proprietary TrimTAC platform, which utilizes the E3 ubiquitin ligase TRIM21 to specifically recognize and selectively clear pathogenic multimeric protein aggregates in neurodegenerative diseases such as Alzheimer's and Parkinson's, while preserving the function of normal monomeric proteins.

The company generates revenue from licensing its TrimTAC platform technology and early drug pipelines to large pharmaceutical companies. 

The company plans to use the seed funding to accelerate the development of the TrimTAC platform, advance early drug pipelines for neurodegenerative diseases, and seek strategic commercial partnerships with large pharmaceutical companies.

## Funding rounds

- Seed, Dec 8, 2025, $10M — Qiming Venture Partners
- Angel, Dec 16, 2020 — Legend Star, Bohe Angel Fund, Shileng Investment

## Investors

- Legend Star (https://capitalatlas.ai/funds/legend-star) — Angel
- Bohe Angel Fund — Angel
- Shileng Investment (https://capitalatlas.ai/funds/shileng-investment) — Angel
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Seed